AMENDMENTS TO THE CLAIMS

In accordance with Rule 1.121, a complete claim listing is presented below, including appropriate status identifiers. Changes in the amended claims are shown by strikethrough for deleted material, and by underlining for added

1-34. (canceled)

- 35. (previously presented) A method of treatment of a bacterial infection characterized by biofilm formation, wherein said bacterial infection comprises *Pseudomonas aeruginosa*, and wherein said method comprises:
- (a) administering to a human or non-human animal in need thereof one or more bacteriophage preparations comprising bacteriophages NCIMB 41174, NCIMB 41175, NCIMB 41176, NCIMB 41177, NCIMB 41178 and NCIMB 41179, wherein said bacteriophages target and kill said *Pseudomonas aeruginosa* present in the biofilm; and
- (b) sequentially administering one or more antibiotics active against a bacterial species present in the biofilm, wherein said one or more antibiotics is administered after the bacteriophages have commenced replication in a targeted *Pseudomonas aeruginosa* present in the biofilm.
- 36. (previously presented): The method of claim 35, wherein the bacteriophages are employed in the form of a single combined bacteriophage preparation.
- 37. (previously presented): The method of claim 36, wherein said combined bacteriophage preparation comprises a plurality of bacteriophages capable of infecting the *Pseudomonas aeruginosa*, each member of said plurality of bacteriophages having a different strain specificity.

38-39. (canceled)

40. (previously presented): The method of claim 35, wherein said infection is an infection selected from infection of a skin burn or other skin wound, a lung

infection, an ocular infection, an ear infection, a urinary infection or infection associated with a medical device or implant.

41. (previously presented): The method of claim 40, wherein said infection is an ear infection.

42-46. (canceled)

- 47. (previously presented): A method of treatment of a bacterial infection characterized by biofilm formation, wherein said bacterial infection comprises *Pseudomonas aeruginosa*, and wherein said method comprises:
- (a) administering to a human or non-human animal in need thereof one or more bacteriophage preparations comprising bacteriophages, wherein said one or more bacteriophages target and kill said *Pseudomonas aeruginosa* present in the biofilm; and
- (b) sequentially administering one or more antibiotics active against a bacterial species present in the biofilm, wherein said one or more antibiotics is administered after the bacteriophages have commenced replication in a targeted *Pseudomonas aeruginosa* present in the biofilm,

wherein a panel of bacteriophages is employed consisting of NCIMB 41174, NCIMB 41175, NCIMB 41176, NCIMB 41177, NCIMB 41178, NCIMB 41179, and

said panel of bacteriophages is employed in the form of a single combined bacteriophage preparation for use in treating an ear infection.

48-75. (canceled)

76. (previously presented): The method of claim 35, wherein administration of said one or more antibiotics is delayed by at least one day after administration of said one or more bacteriophage preparations.

77. (canceled)